Several quinolones and antitumor compounds were tested as inhibitors of purified calf thymus topoisomerase II in unknotting, catenation, radiolabeled DNA cleavage, and quantitative nonradiolabeled cleavage assays. The antitumor agents and ellipticine demonstrated drug-enhanced topoisomerase II DNA cleavage (the concentration of drug that induced 50% of the maximal DNA cleavage in the test system [CC50]) at levels of s5 ,ug/ml. Nalidixic acid, norfloxacin, and oxolinic acid did not induce significant topoisomerase II DNA cleavage, whereas ciprofloxacin did induce some cleavage above background levels. CP-67,015, a new 6,8-difluoro-7-pyridyl 4-quinolone which possesses potent antibacterial activity, inhibited bacterial DNA gyrase at 0.125 ,ug/ml in a nonradioactive DNA cleavage assay. Unlike other quinolones characterized to date, CP-67,015 was shown to strongly enhance topoisomerase II-induced radiolabeled DNA cleavage with a CC50 of 33 ,ug/ml and demonstrated cleavage in a nonradiolabeled DNA cleavage assay with a CC50 of 73 ,ug/ml. The topoisomerase 1I-mediated cleavage of DNA by CP-67,015 is consistent with its reported clastogenic effect on DNA in cell culture and its positive mutagenic response in mouse lymphoma cells. In vitro topoisomerase II catalytic and cleavage assays are useful for gaining preliminary information concerning the possible interaction(s) of some quinolones with eucaryotic topoisomerase II which may relate directly to their safety (mutagenicity, clastogenicity, or both) in human and veterinary medicinal usage.In vitro DNA cleavage mediated by mammalian topoisomerase II has been reported to occur (in the absence of drug) at high enzyme to DNA ratios (17,19) and to be enhanced by antitumor compounds such as 4'-(9-acridinylamino)methanesulfon-m-aniside (m-AMSA), ellipticine, 4,22,24,29,30,39). At the same time, these compounds have shown variable inhibitory effects on the catalytic activity of the enzyme (2, 4, 29). Since this class of drugs has also been associated with DNA breakage observed in cell culture, it has been suggested that enhanced topoisomerase II-mediated DNA cleavage is an important mechanism for the antitumor effects of these agents (4,6,20,21,24). Quinolone antibacterial agents are thought to exert their effects by a similar interference with bacterial DNA gyrase (6,14,23,33), the bacterial homolog of eucaryotic topoisomerase II (15,18,21,37). This class of antibacterial agents has recently been introduced into clinical use (1, 38). Since interaction with topoisomerase II is central to the activity of both quinolones and antitumor agents, it is of interest from a safety standpoint (5, 12, 13) to determine the effects of quinolone antibacterial agents on mammalian topoisomerase II, especially in light of the recent controversy over the mechanism of action of 4-quinolone antibacterial agents as to whether quinolones bind to DNA, gyrase, or the ternary complex of DNA gyrase (7,11,13,32,36).Several different assays have been developed by others (16-19, 21, 22, 27-29, 37, 40) ...